[Use of dexamethasone as an antiemetic in patients with breast cancer treated with the CMF regimen].

The antiemetic efficacy of dexamethasone (Dexaven) was examined in patients with breast cancer during chemotherapy CMF (cyclophosphamide, methotrexate and 5-fluorouracil) in comparison with patients treated identically but without dexamethasone. Comparison of the revealed statistically significant lower nausea incidence (p < 0.025) and lower vomiting incidence (p < 0.025) in the group of patients receiving dexamethasone. The results confirm value of dexamethasone as an effective and safe antiemetic agent using during chemotherapy CMF.